Christian Buske

This Phase 2 trial tests whether adding carfilzomib to ibrutinib improves outcomes for people with Waldenström's macroglobulinemia, a rare blood cancer. About 99 participants will receive either the combination or ibrutinib alone. The goal is to see if the combo leads to higher r…

This study tests a new chemotherapy-free treatment for marginal zone lymphoma, a slow-growing blood cancer. It combines two drugs, Copanlisib and Rituximab, to see if they can control the disease better than Rituximab alone, while avoiding harsh chemo side effects. The trial incl…

This phase 2 trial tests obinutuzumab, a targeted antibody, in 56 people with newly diagnosed marginal zone lymphoma who need treatment but cannot have or have failed local therapy. The goal is to see if this drug can shrink tumors without the side effects of chemotherapy. Partic…

This study tests a chemotherapy-free combination of three drugs (bortezomib, rituximab, and ibrutinib) in 53 people with newly diagnosed Waldenström's macroglobulinemia, a rare blood cancer. The goal is to see if this approach can keep the disease from getting worse for at least …